CCNU chemotherapy in adult patients with tumors of the basal ganglia and brain stem

A. Pompili, A. Riccio, B. Jandolo, M. Fontana

Research output: Contribution to journalArticlepeer-review

Abstract

The present investigation evaluates those few patients of the authors' series with basal ganglia and brain-stem tumor who refused either surgical decompression and biopsy or radiation therapy. Four patients were suffering from tumors of the basal ganglia and 3 from brain-stem tumors; all the tumors were diagnosed by classical neuroradiological investigations and computerized tomography. The patients were given CCNU by mouth, 13 mg/sq m every 6 weeks. No toxicity was recorded. Mean survival was 19 weeks for patients with basal ganglia tumors and 48 wk for those with brain-stem tumors. All patients were evaluated with respect to the quality of survival. Results were compared with those obtained in a control group of patients who received methylprednisolone therapy only.

Original languageEnglish
Pages (from-to)361-363
Number of pages3
JournalJournal of Neurosurgery
Volume53
Issue number3
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'CCNU chemotherapy in adult patients with tumors of the basal ganglia and brain stem'. Together they form a unique fingerprint.

Cite this